Table 1

Baseline patient characteristics

CharacteristicsPatients (N=25)%
Age at enrollment (years)
Median (range)59 (33–78)
<60 years1352
≥60 years1248
Sex
Female1872
Male728
Eastern Cooperative Oncology Group performance status
000
125100
Tumor histology
Adenocarcinoma936
Undifferentiated carcinoma1456
Squamous cell carcinoma28
Time to trial since first diagnosis (years)
Median (range)0.9 (0.3–4.5)
<6 months624
6 months–1 year832
1 year–2 years520
≥2 years624
Number of previous anticancer lines of treatment
Median (range)2 (1–5)
1832
2728
3416
4/5624
Mismatch-repair (MMR)/microsatellite status (N=11)
Proficient-MMR/microsatellite-stable11100
Deficient-MMR/microsatellite-instability high00
PD-L1 status (H-score)
0936
1–1501248
150–300416
PD-L1 expression status*
Positive936
Negative1664
Tumor infiltrating lymphocytes (TILs) infiltration score
0 (no TILs)14
1 (few TILs)1144
2 (moderate infiltration of TILs)416
3 (intense infiltration of TILs)936
  • *Programmed cell death ligand-1 (PD-L1) expression was considered positive if immunohistochemistry was 3+ or 2+ in ≥5% cells.